Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

PURPOSE: BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 inhibitor, has pronounced activity in patients with metastatic melanoma, but its activity in patients with BRAF V600E–positive me...

Descripción completa

Detalles Bibliográficos
Autores principales: Kopetz, Scott, Desai, Jayesh, Chan, Emily, Hecht, Joel Randolph, O'Dwyer, Peter J., Maru, Dipen, Morris, Van, Janku, Filip, Dasari, Arvind, Chung, Woonbook, Issa, Jean-Pierre J., Gibbs, Peter, James, Brian, Powis, Garth, Nolop, Keith B., Bhattacharya, Suman, Saltz, Leonard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2015
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669589/
https://www.ncbi.nlm.nih.gov/pubmed/26460303
http://dx.doi.org/10.1200/JCO.2015.63.2497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669589/
https://www.ncbi.nlm.nih.gov/pubmed/26460303
http://dx.doi.org/10.1200/JCO.2015.63.2497

Ejemplares similares